Clinical journal of the American Society of Nephrology : CJASN

Use of Glucagon-Like Peptide-1 Drugs and Risks of Hospital Stay and Death in People with Advanced Kidney Disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Semaglutide reduced the risk of clinical outcomes and death from cardiovascular causes in patients with chronic kidney disease and type 2 diabetes.

  • The clinical trial FLOW demonstrated a benefit of semaglutide in chronic kidney disease patients.
  • The potential impact of GLP-1 receptor agonists on patients with end-stage kidney disease remains unclear.
  • Further evaluation is needed to determine the effects of GLP-1RA use in incident end-stage kidney disease patients on clinical outcomes.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Feb '26
Treatment with GLP-1 Receptor Agonists is Linked to Better Results in Arteriovenous Fistulas
top 5% journal
cited by 1 paper
journal article
Sep '25
Glucagon-like peptide-1 receptor drugs linked to lower death, heart, and mental health risks in people with psoriasis
top 5% journal
cited by 17 papers
journal article
Mar '22
Glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors and their link to death risk in people with type 2 diabetes and advanced kidney disease
top 2% journal
cited by 78 papers
research support, non-u.s. gov't
Jun '26
Comparison of Different Diabetes Drugs Acting on GLP-1 Receptors and Their Effects on Kidney Health in Type 2 Diabetes
top 5% journal
cited by 1 paper
journal article
Jan '26
Kidney outcomes with SGLT2 inhibitors compared to GLP-1 receptor agonists in people with type 2 diabetes
top 2% journal
cited by 2 papers
journal article
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Dec '24
Effectiveness and treatment continuation of GLP-1 receptor agonists versus DPP-4 inhibitors in advanced and end-stage kidney disease
top 20% journal
cited by 3 papers
comparative study
Jan '26
GLP-1 Drugs and Their Role in Preventing Repeat Heart Attacks and Strokes in People with Type 2 Diabetes: Evidence from Across the Country
top 5% journal
cited by 8 papers
journal article
Feb '24
Heart and kidney benefits of empagliflozin compared to GLP-1 receptor drugs: final year results from the EMPRISE study
top 2% journal
cited by 27 papers
research support, u.s. gov't, p.h.s.
Jun '26
Semaglutide and the risk of major heart and brain blood vessel problems in people with type 2 diabetes and rheumatoid arthritis
top 5% journal
cited by 1 paper

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief